CLINICAL_TRIALS
trial_result
· 2023-11-18
Clinical Trial Update: Phase III Copanlisib in Rituximab-refractory iNHL [Phase 3]
Summary
Phase III trial update for copanlisib in rituximab-refractory indolent non-Hodgkin lymphoma has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bayer | Conditions: Lymphoma, Non-Hodgkin | Phase 3 | Status: COMPLETED | Results posted: 2023-11-18